A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
Completed
Radboud University
Phase 1
2015-11-01
This study aims to provide the evidence that 150mg of cobicistat will have the same effect on
the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with
atazanavir 300mg.
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
Completed
AbbVie
Phase 3
2015-12-01
The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the
combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic
hepatitis C virus (HCV) infection.
Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
Completed
European Egyptian Pharmaceutical Industries
Phase 1
2015-12-01
An open label randomized, single dose, two-way crossover bioequivalence study to determine
the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European
Egyptian Pharmaceutical Industries, Egypt) versus Daklinza 60 mg tablets (Bristol-Myers
Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
Completed
Genuine Research Center, Egypt
Phase 1
2015-12-01
An open label randomized, single dose, two-way crossover bioequivalence study to determine
the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European
Egyptian Pharmaceutical Industries, Egypt) versus Daklinza 60 mg tablets (Bristol-Myers
Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
